ADIL - EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use Disorder | Benzinga
Wednesday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced patent number 11,905,562 was issued on February 20, 2024, by the United States Patent and Trademark Office.
The patent covers the company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
The company says the new patent strengthens Adial’s patent portfolio and covers AD04’s ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
“We are proud to be awarded another important patent that broadens our ...